

Merck resubmits NDA for ezetimibe, atorvastatin

03 January 2013 | Regulatory | By BioSpectrum Bureau

Merck resubmits new drug application for ezetimibe, atorvastatin



Singapore: US FDA has acknowledged the resubmission of a New Drug Application (NDA) for ezetimibe and atorvastatin tablets, an investigational combination medicine developed by Merck.

Merck expects the FDA's review to be completed during the first half of 2013. Merck is continuing to move forward with planned filings for the ezetimibe and atorvastatin combination tablet in additional countries around the world.